Morning, Afternoon Exercise May Cut Diabetes Risk
Medically reviewed by Drugs.com.
By Lori Solomon HealthDay Reporter
TUESDAY, Sept. 26, 2023 -- Morning and afternoon physical activity are associated with a lower risk for developing type 2 diabetes, according to a study published online Sept. 20 in Diabetologia.
Caiwei Tian, from Harvard University in Cambridge, Massachusetts, and colleagues examined the relationship between morning, afternoon, or evening physical activity and consistency (e.g., routine) and the risk for type 2 diabetes. The analysis included data from 93,095 U.K. Biobank participants (mean age, 62 years) free from type 2 diabetes who wore a wrist-worn accelerometer for one week.
The researchers observed a protective association between morning and afternoon exercise with type 2 diabetes, with no differences between metabolic equivalent of task (MET)-measured morning and afternoon physical activity. When adjusting for lifestyle factors (e.g., sleep time and diet), the effect of a substitution between afternoon and evening physical activity was attenuated. There was no association seen for consistency of MET-measured physical activity and type 2 diabetes. At all times of day, moderate-to-vigorous and vigorous physical activity were associated with a lower risk for type 2 diabetes.
"The time of the day when being active may matter for mitigating the risk of type 2 diabetes, but overall physical activity, regardless of time of day and consistency, is the most important," the authors write.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted September 2023
Read this next
AI-Assisted Contours Superior to Cognitively Defined Prostate Cancer Contours
WEDNESDAY, July 3, 2024 -- Artificial intelligence (AI)-assisted definition of prostate cancer contours reduces underestimation of the extent of prostate cancer, according to a...
Mean Cost of Bringing New Drug to U.S. Market Is $879.3 Million
TUESDAY, July 2, 2024 -- The mean cost of developing a new drug for the U.S. market is estimated to be $879.3 million when both drug development failure and capital costs are...
Patient–Primary Care Provider Language Concordance Tied to Better Outcomes
TUESDAY, July 2, 2024 -- Patient-family physician language concordance is associated with a lower risk for adverse outcomes, according to a study published online June 3...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.